Commodities● Neutral

Raymond James Boosts DK to $90 Target Despite Value Warning

By AlphaScala Research DeskSource reporting: gurufocus.comEditorial standards1 views
Raymond James Boosts DK to $90 Target Despite Value Warning

Raymond James lifted its Delek US Holdings target to $90 from $72. GuruFocus data shows a GF Value of $22.65, a 21x trailing P/E, and $24.2 million in insider selling over three months.

AlphaScala Research Snapshot
Live stock context for companies directly referenced in this story
This panel uses AlphaScala-native stock data — proprietary scoring and live snapshots.

Raymond James kept its Outperform rating on Delek US Holdings and raised the price target to $90 a share from $72, analyst Justin Jenkins said on Oct. 3. The 25% increase in the target reflects confidence the refiner can outperform, the note said.

Delek, which refines and markets petroleum products across the U.S., had a market value of about $4.59 billion at the time of the update.

GuruFocus data paint a sharply different picture. The stock's GF Value of $22.65 implies a 230.7% overvaluation against the $74.91 session price. The trailing P/E ratio of 21.04x is roughly three times the five-year median of 7.29x, and the overall GF Score of 47/100 reflects a moderate financial-health reading. Within that score, the growth rank stands at 1/10 and the valuation rank at 1/10, while profitability ranks 6/10.

Insider activity in the past three months showed $24.2 million in sell orders, with six insiders trimming positions against one adding. Three institutional investors hold the stock, according to the data.

Raymond James's $90 target sits 20% above the current price. The split between the sell-side target and the GF Value metric is unusually wide, the data show.

How this story was producedLast reviewed Sep 14, 2026

Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.

Editorial Policy·Report a correction·Risk Disclaimer

Related Tools & Research